MAYO CLINIC

1-800-533-1710

Muscular Dystrophy Gene Panel

MDYSP

PATIENT NAME				ORDER NUMBER
TESTING, MDYSP_ABNORMAL				**M311000224**
PATIENT ID SA00154804	DATE OF BIRTH 11/11/2001	AGE 20 Y	SEX Male	REQUESTED BY CLIENT CLIENT
COLLECTED 10/11/2022, 12:00 AM	RECEIVED 10/13/2022, 3:29 PM	REPORTED 10/14/2022, 4:24 PM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location. 7028846 MCL RochesterCampus Rochester MN 55901				CLIENT ORDER NUMBER SA00154804 CLIENT MRN SA00154804

TEST DESCRIPTION

Evaluation of 75 genes associated with muscular dystrophy

SPECIMEN

WB Whole Blood

RESULT SUMMARY

Pathogenic Variants Detected

RESULT

Gene (Transcript)	Variant	Zygosity	Classification
SELENON NM_020451.2	c.943G>A p.Gly315Ser (p.G315S) chr1(GRCh37):g.26136244G>A	homozygous	PATHOGENIC

The following homozygous PATHOGENIC variant was detected:
SELENON (NM_020451.2), chr1(GRCh37):g.26136244G>A, c.943G>A, p.Gly315Ser (p.G315S)

No additional reportable variants were detected within all other tested genes. See the Genes Analyzed section for a complete list of genes evaluated by this assay.

INTERPRETATION

SELENON c.943G>A (p.Gly315Ser), PATHOGENIC
The homozygous c.943G>A (p.Gly315Ser) missense variant in the SELENON gene (MIM:606210) is classified as pathogenic. Pathogenic variants in the SELENON gene have been associated with autosomal recessive rigid spine muscular dystrophy and autosomal recessive congenital myopathy with fiber type disproportion. This variant has been reported in numerous affected individuals in the homozygous state or compound heterozygous state with a second known pathogenic SELENON variant (1-5). Different missense variants (p.Gly315Arg, p.Gly315Asp) also reported to be pathogenic occur at this position (6,7). This variant has been observed at a very low frequency in exome and/or genome sequencing data gathered from large, multi-ethnic cohorts, suggesting it is a rare variant (8,9). Additionally, an in silico meta-predictor suggests that this amino acid change may impact protein function. This result is supportive of a diagnosis of a SELENON-related disorder for this individual. Clinical correlation is recommended.

This result should be interpreted in the context of clinical findings, family history, and other laboratory testing.

Consultation with a genetics professional is recommended for interpretation of this result and to determine whether reproductive risk assessment and familial testing may be of benefit to this family. Genetic testing for family members is available by ordering FMTT / Familial Mutation, Targeted Testing for the specific variant(s) detected. Please contact the laboratory at 1-800-533-1710 or the online test catalog at www.mayocliniclabs.com for information about FMTT.

PATIENT NAME				ORDER NUMBER
TESTING, MDYSP_ABNORMAL				**M311000224**
PATIENT ID SA00154804	DATE OF BIRTH 11/11/2001	AGE 20 Y	SEX Male	REQUESTED BY CLIENT CLIENT
COLLECTED 10/11/2022, 12:00 AM	RECEIVED 10/13/2022, 3:29 PM	REPORTED 10/14/2022, 4:24 PM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location.				CLIENT ORDER NUMBER SA00154804
7028846 MCL RochesterCampus Rochester MN 55901				CLIENT MRN SA00154804

REFERENCES:
1) Ferreiro A, Quijano-Roy S, Pichereau C, et al. Mutations of the selenoprotein N gene, which is implicated in rigid spine muscular dystrophy, cause the classical phenotype of multiminicore disease: reassessing the nosology of early-onset myopathies. Am J Hum Genet. 2002;71(4):739-749. doi:10.1086/342719 (PMID 12192640)
2) Schara U, Kress W, Bönnemann CG, et al. The phenotype and long-term follow-up in 11 patients with juvenile selenoprotein N1-related myopathy. Eur J Paediatr Neurol. 2008;12(3):224-230. doi:10.1016/j.ejpn.2007.08.011 (PMID 17951086)
3) Maiti B, Arbogast S, Allamand V, et al. A mutation in the SEPN1 selenocysteine redefinition element (SRE) reduces selenocysteine incorporation and leads to SEPN1-related myopathy. Hum Mutat. 2009;30(3):411-416. doi:10.1002/humu.20879 (PMID 19067361)
4) Maggi L, Scoto M, Cirak S, et al. Congenital myopathies--clinical features and frequency of individual subtypes diagnosed over a 5-year period in the United Kingdom. Neuromuscul Disord. 2013;23(3):195-205. doi:10.1016/j.nmd.2013.01.004 (PMID 23394784)
5) Nicolau S, Liewluck T, Tracy JA, Laughlin RS, Milone M. Congenital myopathies in the adult neuromuscular clinic: Diagnostic challenges and pitfalls. Neurol Genet. 2019;5(4):e341. Published 2019 Jun 4. doi:10.1212/NXG.0000000000000341 (PMID 31321302)
6) Scoto M, Cirak S, Mein R, et al. SEPN1-related myopathies: clinical course in a large cohort of patients. Neurology. 2011;76(24):2073-2078. doi:10.1212/WNL.0b013e31821f467c (PMID 21670436)
7) Natera-de Benito D, Ortez C, Jou C, et al. The Phenotype and Genotype of Congenital Myopathies Based on a Large Pediatric Cohort. Pediatr Neurol. 2021;115:50-65. doi:10.1016/j.pediatrneurol.2020.11.002 (PMID 33333461)
8) dbSNP: www.ncbi.nlm.nih.gov/snp; Sherry ST, Ward M and Sirotkin K. dbSNP-Database for Single Nucleotide Polymorphisms and Other Classes of Minor Genetic Variation. Genome Res. 1999;9:677-679 (PMID 10447503)
9) gnomAD Browser: gnomad.broadinstitute.org/; Karczewski K, Francioli LC, MacArthur DG, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020; 581(7809):434-443 (PMID 32461654)

METHOD

Next generation sequencing (NGS) and/or Sanger sequencing was performed to test for the presence of variants in coding regions and intron/exon boundaries of the genes analyzed, as well as some other regions that have known pathogenic variants. The human genome reference GRCh37/hg19 build was used for sequence read alignment. At least 99% of the bases are covered at a read depth over 30X. Sensitivity is estimated at above 99% for single nucleotide variants, above 94% for indels less than 40 base pairs (bp), above 95% for deletions up to 75 bp and insertions up to 47 bp. NGS, and/or a polymerase chain reaction (PCR)-based quantitative method was performed to test for the presence of deletions and duplications in the genes analyzed. See the Genes Analyzed field for a list of genes tested.

There may be regions of genes that cannot be effectively evaluated for sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high GC content, and repetitive sequences. Confirmation of select reportable variants was performed by alternate methodologies based on internal laboratory criteria. See www.mayocliniclabs.com (TEST ID MDYSP) for details regarding genes with regions not routinely covered.

GENES ANALYZED

PATIENT NAME				ORDER NUMBER
TESTING, MDYSP_ABNORMAL				**M311000224**
PATIENT ID SA00154804	DATE OF BIRTH 11/11/2001	AGE 20 Y	SEX Male	REQUESTED BY CLIENT CLIENT
COLLECTED 10/11/2022, 12:00 AM	RECEIVED 10/13/2022, 3:29 PM	REPORTED 10/14/2022, 4:24 PM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location. 7028846 MCL RochesterCampus Rochester MN 55901				CLIENT ORDER NUMBER SA00154804 CLIENT MRN SA00154804

ACTA1, ANO5, B3GALNT2, B4GAT1, BAG3, BIN1, BVES, CAPN3, CAV3, CAVIN1, CHKB, COL12A1, COL6A1, COL6A2, COL6A3, CRPPA, CRYAB, DAG1, DES, DMD, DNAJB6, DNM2, DPM1, DPM2, DPM3, DYSF, EMD, FHL1, FKRP, FKTN, FLNC, GAA, GMPPB, GNE, GOSR2, HNRNPA1, HNRNPA2B1, HNRNPDL, INPP5K, ITGA7, JAG2, LAMA2, LARGE1, LDB3, LMNA, MATR3, MSTO1, MYH7, MYOT, PLEC, POGLUT1, POMGNT1, POMGNT2, POMK, POMT1, POMT2, RXYLT1, SELENON, SGCA, SGCB, SGCD, SGCG, SQSTM1, SUN1, SUN2, SYNE1, TCAP, TIA1, TMEM43, TNPO3, TOR1AIP1, TRAPPC11, TRIM32, TTN and VCP

DISCLAIMER

Clinical Correlations
An online research opportunity called GenomeConnect (genomeconnect.org), a project of ClinGen, is available for the recipient of this genetic test. This patient registry collects de-identified genetic and health information to advance the knowledge of genetic variants. Mayo Clinic is a collaborator of ClinGen. This may not be applicable for all tests.

If testing was performed because of a clinically significant family history it is often useful to first test an affected family member. Detection of a reportable variant(s) in an affected family member would allow for more informative testing of at risk individuals.

To discuss the availability of further testing options or for assistance in the interpretation of these results, Mayo Clinic Laboratory genetic counselors can be contacted at 1-800-533-1710.

Technical Limitations
Next generation sequencing may not detect all types of genomic variants. In rare cases, false negative or false positive results may occur. The depth of coverage may be variable for some target regions, but assay performance below the minimum acceptable criteria or for failed regions will be noted. Given these limitations, negative results do not rule out the diagnosis of a genetic disorder. If a specific clinical disorder is suspected, evaluation by alternative methods can be considered.

There may be regions of genes that cannot be effectively evaluated for sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high GC content, and repetitive sequences. Confirmation of select reportable variants was performed by alternate methodologies based on internal laboratory criteria.

Additionally, low level mosaic variants may not be detected.

This test is not designed to differentiate between somatic and germline variants. If there is a possibility that any detected variant is somatic, additional testing may be necessary to clarify the significance of results.

Genes may be added or removed based on updated clinical relevance. Please refer to the Targeted Genes and Methodology Details for the Muscular Dystrophy Gene Panel in the Special Instructions section of the Test Catalog for the most up to date list of genes included in this test.

Reclassification of Variants Policy

PATIENT NAME				ORDER NUMBER
TESTING, MDYSP_ABNORMAL				**M311000224**
PATIENT ID SA00154804	DATE OF BIRTH 11/11/2001	AGE 20 Y	SEX Male	REQUESTED BY CLIENT CLIENT
COLLECTED 10/11/2022, 12:00 AM	RECEIVED 10/13/2022, 3:29 PM	REPORTED 10/14/2022, 4:24 PM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location. 7028846 MCL RochesterCampus Rochester MN 55901				CLIENT ORDER NUMBER SA00154804 CLIENT MRN SA00154804

See www.mayocliniclabs.com (TEST ID MDYSP) for information regarding the laboratory's policy for reclassification of variants.

Variant Evaluation
Variant curation is performed using published ACMG-AMP recommendations as a guideline. Other gene-specific guidelines may also be considered. Variants classified as benign or likely benign are not reported.

Results from in silico evaluation tools may change over time and should be interpreted with caution and professional clinical judgment.

TEST CLASSIFICATION
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

RELEASED BY

Niu, Zhiyv, Ph.D.

Code : MCR Laboratory : Mayo Clinic Laboratories - Rochester Main Campus Address : 200 FIRST STREET SW
Lab Director : WILLIAM G MORICE, II MD, PhD CLIA Certificate : 24D0404292 ROCHESTER MN 55905